Intraosseous administration of exogenous FGF2, a muscle-derived osteogenic growth factor, has demonstrated its efficacy in enhancing bone formation in ovariectomized (OVX) rats with osteoporosis [149]. The gene discussed is FGF2; the disease is osteoporosis.